By VETTAPHARMA reporter – Derek Roche: AstraZeneca reported that Imfinzi (durvalumab) plus Imjudo (tremelimumab) combined with lenvatinib and transarterial chemoembolisation (TACE) significantly reduced the risk of disease progression or death in patients with embolisation-eligible unresectable hepatocellular carcinoma (HCC), meeting the primary endpoint of the Phase III EMERALD-3 trial.
The regimen demonstrated a statistically significant and clinically meaningful improvement in progression-free survival compared with TACE alone.
At an interim analysis, the combination also showed a trend toward improved overall survival, a key secondary endpoint, although final overall survival data remain immature. The findings extend AstraZeneca’s effort to move its dual-immunotherapy STRIDE regimen into earlier stages of liver cancer treatment beyond currently approved advanced-disease settings.
EMERALD-3 evaluated the STRIDE regimen, consisting of a single priming dose of Imjudo added to Imfinzi followed by regular Imfinzi dosing, alongside lenvatinib and TACE. Patients received systemic therapy before and during embolisation treatment, an approach designed to improve disease control in a population where recurrence and progression remain common despite locoregional intervention.
The global Phase III study enrolled 760 patients across 171 centres in 22 countries with unresectable HCC eligible for embolisation. Patients were randomized to receive either Imfinzi, Imjudo, lenvatinib and TACE; STRIDE plus TACE; or TACE alone. The primary endpoint assessed progression-free survival for the quadruplet regimen versus TACE alone.
Hepatocellular carcinoma is the most common form of liver cancer and remains one of the leading causes of cancer-related mortality worldwide. In patients eligible for embolisation procedures, disease progression or recurrence frequently occurs within months following treatment, highlighting the need for systemic therapies capable of improving long-term disease control.
Safety findings were consistent with the established profiles of Imfinzi, Imjudo and lenvatinib, with no new safety signals identified during the study. AstraZeneca stated that the results will be presented at a future medical meeting and discussed with regulatory authorities globally.
The data further strengthen AstraZeneca’s liver cancer franchise, which already includes approved use of the STRIDE regimen in unresectable HCC based on the Phase III HIMALAYA study. Positive EMERALD-3 findings may support expansion of the regimen into earlier-stage disease, significantly increasing the eligible treatment population.
For patients, the findings suggest that integrating immunotherapy and targeted therapy alongside embolisation may delay disease progression in a setting where treatment options remain limited. From a commercial perspective, earlier-stage liver cancer expansion could further strengthen Imfinzi’s growth trajectory within the increasingly competitive hepatocellular carcinoma market.
Quick FAQs
1. What is the STRIDE regimen?
The STRIDE regimen combines a single priming dose of Imjudo (tremelimumab) with regular Imfinzi (durvalumab) treatment to enhance anti-tumor immune responses.
2. What were the key EMERALD-3 results?
The combination of Imfinzi, Imjudo, lenvatinib and TACE significantly improved progression-free survival compared with TACE alone.
3. What is the EMERALD-3 study?
EMERALD-3 is a global Phase III trial evaluating Imfinzi, Imjudo, lenvatinib and TACE in patients with embolisation-eligible unresectable hepatocellular carcinoma.
4. What is hepatocellular carcinoma?
Hepatocellular carcinoma is the most common type of liver cancer and often develops in patients with chronic liver disease or cirrhosis.
5. How large was the EMERALD-3 trial?
The study enrolled 760 patients across 171 centres in 22 countries.
6. Why are the EMERALD-3 findings important?
The results support moving AstraZeneca’s immunotherapy-based regimen into earlier liver cancer treatment settings where recurrence risk remains high.
